Q: I have done well with this stock in my TFSA but have trouble knowing when to sell this momentum play. Do you look at technicals , ie. volume, RSA ? Do you look at market attitude towards the sector, ie. what’s hot what’s not ? Do you consider portfolio composition ? Recognizing this money is for speculation, not investing, what would you do if YOU owned it with a 45% TFSA weighting ?Thanks Derek
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Hi,
I also held on to the LTRX shares that I rec'd via ITC because they have been in business for a long time, their products are in a diverse range of industries, the SaaS and IoT aspects and a big backlog. I interpret the backlog as partly due to factors beyond their control so this could be a negative.
You stated in a previous answer that good growth is expected this year. Do you still see good growth and what is your take on the recent results? Thank you.
I also held on to the LTRX shares that I rec'd via ITC because they have been in business for a long time, their products are in a diverse range of industries, the SaaS and IoT aspects and a big backlog. I interpret the backlog as partly due to factors beyond their control so this could be a negative.
You stated in a previous answer that good growth is expected this year. Do you still see good growth and what is your take on the recent results? Thank you.
-
Organigram Global Inc. (OGI $1.96)
-
Aphria Inc. (APHA $16.55)
-
Supreme Cannabis Company Inc. (The) (FIRE $0.34)
-
Aurora Cannabis Inc. (ACB $5.13)
-
Tilray Brands Inc. (TLRY $7.75)
-
Canopy Growth Corporation (CGC $1.19)
-
HEXO Corp. (HEXO)
Q: I have put in approx $1000 in each of the 7 companies after yesterdays drop, do you see a potential for increase in the short term say 6 months to 1 year? Why is there so much interest in FIRE lately?
Q: Would like to hear your thoughts on Tufin Software Technologies.
-
WELL Health Technologies Corp. (WELL $3.98)
-
PowerShares S&P SmallCap Health Care Portfolio (PSCH $43.11)
Q: A while back I bought a small amount of the PSCH small cap health care fund on your suggestion and it is doing very nicely. I see from watching the comments on WELL, that you also like it. If I have a small amount of cash to deploy (less than a full position), should put it into it WELL or would you advise me to continue to build up the ETF position?
Q: Hello 5i team. What are your thoughts on this company?
Q: Any thoughts on Bluesky Digital Assets. Looking for the next big hype on Crypto. I don't know where to look or if I have missed the Boat
Q: Hi, I would like your opinion about NPTN? Thanks.
Q: What are your thoughts on UGE International? Has it gone up too much to buy now? I am thinking about investing in this vs. Sernova (different companies but have cash for one).
Q: Your thoughts on Kubient Inc.(kbnt on nasdaq).Thanks.
-
Sangoma Technologies Corporation (STC $6.18)
-
Photon Control Inc. (PHO $3.60)
-
StorageVault Canada Inc. (SVI $5.00)
-
Theralase Technologies Inc. (TLT $0.27)
-
GuestLogix Inc. (GXI $0.10)
-
Redishred Capital Corp. (KUT $4.96)
-
Good Natured Products Inc. (GDNP $0.02)
-
WELL Health Technologies Corp. (WELL $3.98)
-
Docebo Inc. (DCBO $23.47)
-
Dye & Durham Limited (DND $3.62)
Q: I am looking for high growth ideas from small caps. From this list, what would be your TOP 3 Picks?
Thanks Valter
Thanks Valter
Q: Mike asked about the valuation of Pyrogenesis today, Feb 16th, commenting that it had never been profitable or cash flow positive. I just wanted to point out that this has changed in fiscal year 2020. The last quarter was very profitable, and the current estimate for fiscal 2020, released on Jan 11th, is for revenue of $14 - 16 million, an increase of approximately 200% since 2019, and net income of 22 - 24 cents per share, compared to a loss of 7 cents per share in 2019. The company is making good progress with their various product lines involving plasma torches for various industrial purposes, plasma atomized metal powder, and plasma waste-to-energy systems.
Q: Any thoughts on this small cap?
Q: Good morning,
Could I get your take on GRID? Sounds exciting but I haven’t been able to find out much regarding financials.
Could I get your take on GRID? Sounds exciting but I haven’t been able to find out much regarding financials.
Q: As of today (Feb 13th 2021), this company has a market cap of ~ $1.5 Billion. However, from what I can see (on SEDAR), it has not even come close to having a positive net income or cash flow since its existence. Am I (as an investor) missing something very obvious, of is this just another sign that there is a "bit of exuberance" in the current market ?
Q: Comments on the quarter? Thanks!
Q: Hi, I would be interested in your opinion on PLAN or other companies that might provide low-carbon cement/concrete?
Thanks
Paul
Thanks
Paul
Q: Hello Team,
Could you give me an analysis on this company and is it one you would endorse?
Thank You,
Barry
Could you give me an analysis on this company and is it one you would endorse?
Thank You,
Barry
Q: Can you comment on LI is taking over PLU. Seems like there is a big discount to PLU compared to the price of LI. What should the price of PLU be based on current price of LI. Thanks
Q: My research drudged up this on Kaleyra, do you agree or have anything to add? Was thinking of starting a position.
A cloud computing company offering communications solutions. The company’s SaaS platform supports SMS, voice calls, and chatbots – a product with obvious applications and value in today’s office climate, with the strong push to telecommuting and remote work. Kaleyra boasts over 3,500 customers, who make 3 billion voice calls and sent 27 billion text messages in 2019 (the last year with full numbers available).
Over the past 6 months, KLR shares have shown tremendous growth, appreciating 155%. Kaleyra’s revenues have grown along with the share value. The company’s 3Q20 results hit $38.3 million, the best since KLR went public. While Kaleyra still runs a net earnings loss each quarter, the Q3 EPS was the lowest such loss in the past four quarters.
“Over the past few years, Kaleyra has posted double-digit revenue growth and positive adjusted EBITDA. We forecast revenue growth of 9%, 22%, and 28% for 2020-2022. We project adjusted EBITDA declines in 2020 to reflect public company costs and COVID-19, but growth at over twice the rate of revenue for the following two years. We expect benefits from operating leverage, low-cost tech employees, cost volume discounts as the company expands, and margin improvement from new offerings and geographies. Over the longer term, we believe the company can grow revenue close to 30% with even faster bottom line growth,” .
A cloud computing company offering communications solutions. The company’s SaaS platform supports SMS, voice calls, and chatbots – a product with obvious applications and value in today’s office climate, with the strong push to telecommuting and remote work. Kaleyra boasts over 3,500 customers, who make 3 billion voice calls and sent 27 billion text messages in 2019 (the last year with full numbers available).
Over the past 6 months, KLR shares have shown tremendous growth, appreciating 155%. Kaleyra’s revenues have grown along with the share value. The company’s 3Q20 results hit $38.3 million, the best since KLR went public. While Kaleyra still runs a net earnings loss each quarter, the Q3 EPS was the lowest such loss in the past four quarters.
“Over the past few years, Kaleyra has posted double-digit revenue growth and positive adjusted EBITDA. We forecast revenue growth of 9%, 22%, and 28% for 2020-2022. We project adjusted EBITDA declines in 2020 to reflect public company costs and COVID-19, but growth at over twice the rate of revenue for the following two years. We expect benefits from operating leverage, low-cost tech employees, cost volume discounts as the company expands, and margin improvement from new offerings and geographies. Over the longer term, we believe the company can grow revenue close to 30% with even faster bottom line growth,” .